Skip to main content

23andMe announces $300M deal for your DNA with giant drug company GSK

23andMe will soon be doing a lot more with the gene information it has been collecting — and turning your DNA data into dollar bills.

The home genetics company has teamed up with pharmaceutical giant GlaxoSmithKline (GSK) to design new drugs that could treat diseases like Parkinson’s, among others. Given 23andMe’s substantial genetic database provided by its 5 million customers, the company hopes that a partnership with GSK could provide the necessary data to develop effective therapies.

“Since the inception of 23andMe, our mission has been to help people access, understand and benefit from the human genome,” Anne Wojcicki, the company’s CEO and co-founder, said in a statement. “Today, I am thrilled to announce that we are launching a collaboration with GlaxoSmithKline to accelerate our ability to make those novel treatments and cures a reality.”

This collaboration also involves DNA the company’s has collected from millions of people — and hundreds of millions of dollars. GSK made a $300 million investment in 23andMe as part of the partnership; the pharmaceutical giant will maintain exclusive rights to collaborate with 23andMe in order to develop drugs.

“By working with GSK, we believe we will accelerate the development of breakthroughs,” Wojcicki said. “Our genetic research — powered by millions of customers who have agreed to contribute — combined with GSK’s expertise in drug discovery and development, gives us the best chance for success.”

This collaboration marks the largest such effort to date in the home genetics testing space and hopes to leverage the bevy of data that companies like 23andMe and others have collected thanks to mail-in saliva tests. 23andMe is by far the most popular of these kits, which means it likely has the most to offer a pharmaceutical partner.

23andMe has said that they will ask customers whether they would like to participate in research before using their data, ensuring that adequate consent is attained in the process. “As always, if our customers do not want to participate in research, they can choose to opt out at any time,” Wojcicki wrote.

it was unclear whether the company would contact older customers about inclusion.

This isn’t the first time 23andMe has attempted to utilize its genetic data for scientific purposes. As Wojcicki noted, the research team at the company has published more than 100 scientific papers, and in 2015, the team launched 23andMe Therapeutics “to develop novel treatments and cures based on genetic insights from the consented 23andMe community.” Of course, with the help of GSK, these treatments and cures are likely to go much further.

Editors' Recommendations

Lulu Chang
Former Digital Trends Contributor
Fascinated by the effects of technology on human interaction, Lulu believes that if her parents can use your new app…
Meet the game-changing pitching robot that can perfectly mimic any human throw
baseball hitter swings and misses

Who’s your favorite baseball pitcher? Shane McClanahan? Sandy Alcantara? Justin Verlander? Whoever you said, two of the top sports-tech companies in the U.S. -- Rapsodo and Trajekt Sports -- have teamed up to build a robot version of them, and the results are reportedly uncannily accurate.

Okay, so we’re not talking about walking-talking-pitching standalone robots, as great a sci-fi-tinged MLB ad as that would be. However, Rapsodo and Trajekt have combined their considerable powers to throw a slew of different technologies at the problem of building a machine that's able to accurately simulate the pitching style of whichever player you want to practice batting against -- and they may just have pulled it off, too.

Read more
The best portable power stations
EcoFlow DELTA 2 on table at campsite for quick charging.

Affordable and efficient portable power is a necessity these days, keeping our electronic devices operational while on the go. But there are literally dozens of options to choose from, making it abundantly difficult to decide which mobile charging solution is best for you. We've sorted through countless portable power options and came up with six of the best portable power stations to keep your smartphones, tablets, laptops, and other gadgets functioning while living off the grid.
The best overall: Jackery Explorer 1000

Jackery has been a mainstay in the portable power market for several years, and today, the company continues to set the standard. With three AC outlets, two USB-A, and two USB-C plugs, you'll have plenty of options for keeping your gadgets charged.

Read more
CES 2023: HD Hyundai’s Avikus is an A.I. for autonomous boat and marine navigation
Demonstration of NeuBoat level 2 autonomous navigation system at the Fort Lauderdale International Boat Show

This content was produced in partnership with HD Hyundai.
Autonomous vehicle navigation technology is certainly nothing new and has been in the works for the better part of a decade at this point. But one of the most common forms we see and hear about is the type used to control steering in road-based vehicles. That's not the only place where technology can make a huge difference. Autonomous driving systems can offer incredible benefits to boats and marine vehicles, too, which is precisely why HD Hyundai has unveiled its Avikus AI technology -- for marine and watercraft vehicles.

More recently, HD Hyundai participated in the Fort Lauderdale International Boat Show, to demo its NeuBoat level 2 autonomous navigation system for recreational boats. The name mashes together the words "neuron" and "boat" and is quite fitting since the Avikus' A.I. navigation tech is a core component of the solution, it will handle self-recognition, real-time decisions, and controls when on the water. Of course, there are a lot of things happening behind the scenes with HD Hyundai's autonomous navigation solution, which we'll dive into below -- HD Hyundai will also be introducing more about the tech at CES 2023.

Read more